When Does Dupixent Patent Expiry Occur in the US?
The primary patents protecting Dupixent (dupilumab) in the United States are set to expire around 2035 [1]. However, the exact timeline for market exclusivity can be complex and influenced by various factors, including the patent landscape and potential legal challenges [2].
What is Dupixent Used For?
Dupixent is a prescription medication used to treat moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and other conditions associated with inflammation [3]. It works by targeting key drivers of inflammation in these diseases [3].
How Does Dupixent Work?
Dupixent is a monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) [3]. These interleukins are proteins that play a significant role in the inflammatory pathways of conditions like atopic dermatitis and asthma [3]. By blocking their action, Dupixent helps to reduce inflammation and improve symptoms [3].
Who Manufactures Dupixent?
Dupixent is developed and manufactured by Sanofi and Regeneron Pharmaceuticals [4].
What is the Patent Landscape for Dupixent?
The patent protection for Dupixent is multifaceted, involving multiple patents covering the drug substance, its methods of use, and manufacturing processes [1]. DrugPatentWatch.com tracks these patents, indicating that key patents for Dupixent are expected to expire in the mid-2030s [1]. This provides a period of market exclusivity for the innovators [2].
Can Biosimilars Enter the Market Before Patent Expiry?
Generally, biosimilar versions of biologic drugs like Dupixent cannot enter the market until the relevant patents expire and any periods of exclusivity conclude [5]. The regulatory pathway for biosimilars is designed to ensure that they demonstrate high similarity to the reference product and do not infringe on existing intellectual property rights [5].
What Happens After Patent Expiry for Dupixent?
Once Dupixent's patent protection expires, it opens the door for the potential introduction of biosimilar versions of the drug [5]. Biosimilars are biological products that are highly similar to an already approved reference product, with no clinically meaningful differences in safety, purity, and potency [5]. The availability of biosimilars can lead to increased competition and potentially lower prices for patients and healthcare systems [5].
What Are the Risks Associated with Dupixent?
Like all medications, Dupixent carries potential risks and side effects. Common side effects can include injection site reactions, cold-like symptoms, and conjunctivitis [3]. More serious side effects are rare but can occur [3]. Patients should discuss all potential risks with their healthcare provider [3].
How Much Does Dupixent Cost?
The cost of Dupixent can vary significantly depending on insurance coverage, pharmacy, and geographical location [6]. It is generally considered a high-cost specialty medication.
What Are the Next Steps for Dupixent's Market Life?
Following patent expiry, the market for Dupixent will likely evolve with the introduction of biosimilars. This transition is a standard part of the pharmaceutical lifecycle for successful biologic drugs [5]. The continued availability of treatments for conditions like atopic dermatitis and asthma will be a focus for patients and physicians [3].
Sources
1. DrugPatentWatch.com
2. Sanofi and Regeneron Pharmaceuticals, Investor Relations Information
3. Dupixent Prescribing Information
4. Sanofi and Regeneron Pharmaceuticals, Press Releases
5. U.S. Food and Drug Administration (FDA) Website, Biosimilars
6. Various Online Pharmacy and Insurance Provider Information